Key result
Lipid gene analyses aid dyslipidemia diagnosis, drug discovery, and CAD risk stratification.
Answers are grounded in this paper and cite their sources.
Genetic analyses of plasma lipids provide important insights for the diagnosis, risk stratification, and development of novel therapies for coronary artery disease.
We have learned that low-density lipoprotein (LDL) cholesterol is the cause of atherosclerosis from various aspects, including a single case with familial hypercholesterolemia, other cases with different types of Mendelian dyslipidemias, large-scale randomized controlled trials using LDL cholesterol lowering therapies, and Mendelian randomization studies using common as well as rare variants associated with LDL cholesterol levels. There is no doubt that determinations of genotypes in lipid-associated genes have contributed not only to the genetic diagnosis for Mendelian dyslipidemias but also to the discoveries of novel therapeutic targets. Furthermore, recent studies have shown that such genetic information could provide useful clues for the risk prediction as well as risk stratification in general and in particular population. We provide the current understanding of genetic analyses relating to plasma lipids and coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Tada et al. (2017) conducted a review in Dyslipidemia and Coronary Artery Disease. Genetic analyses was evaluated. Genetic analyses of lipid-associated genes contribute to the diagnosis of Mendelian dyslipidemias, discovery of novel therapeutic targets, and risk stratification for coronary artery disease.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: